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Hereditary non-polyposis colorectal cancer (HNPCC,Lynch syndrome) is an autosomal dominantly inheritedsyndrome predisposing to the early development of
cancers of the colon, rectum, endometrium, small bowel, and
urinary tract and accounts for ∼5% of all colon cancer cases.1
There are at least five genes involved in this cancer predisposi-
tion and they include MLH1,2 MSH2,3 MSH6,4 PMS2, and
PMS1.5 Currently, more than 300 different mutations have
been described in these genes which account for approxi-
mately 500 HNPCC kindreds from different parts of the
world.6 MLH1 and MSH2 genes show abnormalities in more
than 90% of HNPCC families with identified germline
mutations7 (http://www.nfdht.nl). The majority of reported
MLH1 and MSH2 mutations are dispersed throughout the 35
exons of these two genes. However, some changes are
recurrent and are described as founder mutations in particu-
lar populations.8–11 In order to develop efficient DNA testing, it
is important to describe the nature and frequency of
mutations that are characteristic of particular ethnic groups.
The MSH2 and MLH1 mutation spectrum has not been inves-
tigated in the eastern European region and therefore there is
no knowledge about any recurrent mutations which may sig-
nificantly aid in the mutation screening procedures for this
region. Here, we describe the results of DNA/RNA based
mutation sequencing of both the MSH2 and MLH1 genes in a
series of HNPCC families from Poland (89 cases) and the Bal-
tic States (12 cases).
MATERIAL AND METHODS
Patients
A total of 101 unrelated patients affected by colorectal cancer
or an HNPCC associated cancer (endometrium, small bowel,
urinary tract) were from 17 families which fulfilled the
Amsterdam II criteria12 and from 84 families matching our
modified criteria of suspected HNPCC, one colorectal cancer
patient with a first degree relative affected by an HNPCC asso-
ciated cancer, one of whom was diagnosed under the age of 50
years.13 The clinical diagnosis of HNPCC was established or
verified at the Hereditary Cancer Centre, Pomeranian Acad-
emy of Medicine, Szczecin, Poland. Patients used for this study
were ascertained from the following regions: Bydgoszcz (3),
Gdańsk (3), Kielce (14), Kraków (3), Legnica (1), Lublin (2),
Lódz (1), Olsztyn (13), Poznań (7), Riga (3), Szczecin (33),
Tartu (3), Wrocław (5), Vilnius (6), Zielona Góra (4).
DNA isolation
Peripheral blood samples were collected from the patients
after obtaining informed consent. DNA was extracted directly
from leucocytes by the classical phenol purification method or
as described previously.14
DNA sequencing
All exons and exon-intron junctions of MLH1 and MSH2 were
amplified using the same protocols as described previously15
with the same primer sequences as described by Wijnen et
al16 17 for DGGE but without the M13 and GC clamp sequences
at the 5′ end. Dye terminator cycle sequencing reactions were
performed using the ABI PRISM Dye-terminator Cycle
Sequencing Ready Reaction kit (Perkin Elmer) according to
the manufacturer’s recommended protocol. Semi-automated
fluorescence analysis was performed using a 373 A DNA
Sequencer (ABI, Perkin-Elmer).
RNA based sequencing
RNA sequencing template was used for 15 patients in whom
mutations had not previously been detected by genomic DNA
based sequencing. Total RNA was extracted from fresh
lymphocytes using Trizol (Gibko BRL, Life Technologies Inc,
Key points
• The DNA mismatch repair genes MSH2 and MLH1
account for a major proportion of hereditary non-
polyposis colorectal cancer (HNPCC) families. One
approach by which development of an efficient DNA
testing procedure can be implemented is to describe the
nature and frequency of common mutations in particular
ethnic groups.
• We screened 101 HNPCC kindreds from Poland and
the Baltic States fulfilling the Amsterdam II diagnostic
criteria or suspected HNPCC criteria for mutations in
MSH2 and MLH1. Twenty different pathogenic muta-
tions were found, nine in MSH2 and 11 in MLH1. Nine
of these had not previously been described. Among
families which fulfilled the Amsterdam II criteria,
mutations were identified in 59%, and in the remaining
kindreds 29% were found to harbour a change in the
two genes. Recurrent mutations were found in 50% of
examined families with mutations. Two of the most
frequent were a substitution of a for t at the splice donor
site of intron 5 of MSH2 and a missense change
(A681T) in MLH1 found in seven and six families,
respectively.
• Our results in conjunction with others indicate that a
screening system limited to the detection of all reported
mutations will allow the identification of the majority of
small changes present in coding and flanking intronic
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Gaithersburg, MD). cDNA was synthesised with c therm
polymerase (Roche Diagnostics) using 0.5 µg total RNA and
specific primers complementary to the 3′ end of MLH1 and to
the 3′ end of MSH2. PCR products were size fractionated by
agarose gel electrophoresis. Sequencing of the cDNA was as
described previously.18
RESULTS
Unequivocal mutations were detected in 34 families; 16
mutations were identified in MSH2 and 18 mutations in
MLH1. Among families which fulfilled the Amsterdam II cri-
teria mutations were identified in 59% of kindreds. There
were three families that harboured MSH2 changes and seven
Table 1 Polish and Baltic States families with MSH2 and MLH1 germline mutations
and rare exonic variants of unknown significance
Case No/family ID
Gene/exon or intron
change Position of nucleotide Consequence
1/9154 MSH2/2 c.del273TCT 92delL
2/1524 MSH2/3 c.613G>T E205X
3/1882 MSH2/SD5 c.942+3a>t In frame del exon 5
4/4814 MSH2/SD5 c.942+3a>t In frame del exon 5
5/5888 MSH2/SD5 c.942+3a>t In frame del exon 5
6/6797 MSH2/SD5 c.942+3a>t In frame del exon 5
7/LT7* MSH2/SD5 c.942+3a>t In frame del exon 5
8/15105 MSH2/SD5 c.942+3a>t In frame del exon 5
9/17237 MSH2/SD5 c.942+3a>t In frame del exon 5
10/1296 MSH2/7 c.1216C>T R406X
11/6474 MSH2/7 c.1216C>T R406X
12/7167 MSH2/SD10 c.1661+5g>c Out of frame del exon10
13/6609 MSH2/12 c.1771-1772insA Frameshift
14/6506 MSH2/13 c.2131C>T R711X
15/6810 MSH2/SD13 c.2210+1g>c Out of frame del exon13
16/3213 MSH2/14 c.2388delT Frameshift
17/2796 MLH1/1 c.37delG Frameshift
18/7640 MLH1/1 c.83C>T P28L
19/6353 MLH1/1 c.83C>T P28L
20/8162 MLH1/2 c.184C>T Q62X
21/2575 MLH1/4 c.350C>T T117M
22/2683 MLH1/4 c.356-357insAA Frameshift
23/4370 MLH1/SD8 c.677G>T Splice
24/4102 MLH1/10 c. 883delAGgt Out of frame del exon10
25/6774 MLH1/SD12 c.1409+1g>c Splice
26/7576 MLH1/13 c.1489-1490insC Frameshift
27/7848 MLH1/14 c.1668delCCA 553delT
28/6434 MLH1/15 c.1672G>T E558X
29/1821 MLH1/18 c.2041G>A A681T
30/1881 MLH1/18 c.2041G>A A681T
31/7266 MLH1/18 c.2041G>A A681T
32./6802 MLH1/18 c.2041G>A A681T
33/8998 MLH1/18 c.2041G>A A681T
34/ LT-11* MLH1/18 c.2041G>A A681T
35/6609 MSH2/15 c.2558A>C E853A pathogenic?
36/ A1127† MLH1/1 c.55A>T I19F pathogenic?
37/9855 MLH1/10 c.875T>C L292P pathogenic?
38/10388 MLH1/10 c.875T>C L292P pathogenic?
39/3412 MLH1/18 c.2059C>T R687W pathogenic?
*From Lithuania.
†From Estonia.
Bold: mutations not found previously in other populations.









MSH2/1 c.211+9c/g No consequence – polymorphism 32/101
MSH2/6 c.965A/G G322D 19/101
MSH2/9 c.1511-9t/a No consequence – polymorphism 14/101
MSH2/10 c.1661+12g/a No consequence – polymorphism 33/101
MLH1/8 c.655A/G I219V 31/101
MLH1/13 c.1558+14a/g No consequence – polymorphism 5/101
MLH1/14 c.1668-19a/g No consequence – polymorphism 43/101
(B) Rare polymorphisms-silent mutations
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families associated with MLH1 gene mutations. From the
patients matching our modified criteria of suspected HNPCC,
mutations were detected in 29% of families, 13 in MSH2 and
11 in MLH1.
Recurrent mutations were identified in 17 (50%) families
with mutations. Two of the most frequent changes were a
substitution of A to T in the splice donor site of intron 5 of the
MSH2 gene, which represents the most frequent MSH2 muta-
tion reported8 and a missense change, a A681T in MLH1, found
in seven and six families, respectively. Mutations not
described previously in other populations were found in nine
families (highlighted in table 1, fig 1). The pathogenic nature
of the g to c change at 1661+5 was confirmed at the RNA level
by identifying an aberrant transcript which was the result of
exon 10 skipping which resulted in the creation of stop codon.
RNA based sequencing resulted in the detection of an aberrant
MLH1 transcript which was the result of a loss of exon 16, but
no change could be identified in genomic DNA.18 In addition to
Figure 1 MLH1 and MSH2 mutations not described in other populations. Sequence chromatograms of cases 2, 12, 13, 15, 16, 17, 22, 24,
and 27.
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unequivocal mutations, sequence variants of uncertain patho-
logical significance were detected in five families. One of these
alterations (c.875T>C) occurred in two patients (table 1). Fre-
quent and rare MSH2 and MLH1 polymorphisms are summa-
rised in table 2.
A summary of novel missense alterations of unknown sig-
nificance is shown in table 3.
DISCUSSION
The appropriate management of patients from HNPCC
families decreases the risk of cancer and results in a better life
expectancy. The identification of HNPCC families remains
problematical, as the Amsterdam II criteria which rely on
pedigree and clinical data are very restrictive. Indeed the above
Amsterdam II criteria cannot be matched in the majority of
families with MSH2 or MLH1 mutations. At present, the only
method to diagnose HNPCC unequivocally in suspected cases
of this disorder is to identify constitutional mutations in the
genes associated with this disorder. The most accurate method
of detecting germline mutations are molecular analyses using
either DNA or RNA templates for DNA sequencing analysis.
These techniques are complex, time consuming, and expen-
sive. Given the limited resources for routine mutation screen-
ing, it is essential to develop DNA testing protocols further.
One of the most efficient ways of achieving this is to describe
the nature and frequency of population specific mutations in
order to target those changes first. From the results presented
here, it is apparent that two mutations (a to t substitution in
the splice donor site of intron 5 of the MSH2 gene and
missense A681T in MLH1) account for about 40% (12/34) of
mutations identified in Polish HNPCC families. Two other
mutations (1216C>T in MSH2 and 83C>T in MLH1) occurred
in two families (one of which has not previously been
reported) and eight mutations (del273TCT, 2131C>T in MSH2
and 184C>T, 350C>T, 667G>T, g>c at 1409+1, ins C at 1490,
and 1672G>T in MLH1) were observed previously in other
populations. The remaining nine mutations (613G>T, g>c at
1661+5, ins A at 1772, g>c at 2210+1, delT at 2388 in MSH2
and delG at 37, ins AA at 356, delAGgt at 883, delCCA at 1658
in MLH1) were found to be potentially specific for Polish
families as they have not previously been described. Therefore,
the characteristics of mutations identified from Poland and
the Baltic States suggest that it is worthwhile to develop
mutation testing focusing on these changes as a first
approach. The frequency of mutations in families that fulfilled
the Amsterdam II criteria was approximately 60% and in
families suspected of HNPCC around 30%, which is compar-
able with the frequency of mutations identified by other
authors for different populations.19 Therefore, it can be
predicted that the sensitivity of testing of this population for
the reported mutations could be very high. Certainly, the sen-
sitivity of this testing approach will not achieve 100%. False
negative results could potentially occur in families with
missense mutations. In our series, more than 10% of
MSH2/MLH1 mutations involved such an amino acid substitu-
tion (table 3). The missense alteration 2558A→C at codon 853
in exon 15, which resulted in a substitution of glutamic acid
for alanine, seems to be a neutral rare polymorphism as it did
not cosegregate with the disease in the family. In spite of the
location in important functional domains in the MLH1
protein, two missense alterations, I19F and L292P, could not be
exclusively associated with the disease as they may represent
polymorphisms. The missense alteration 2059C→T at codon
687 in exon 18 that resulted in substitution of arginine for
tryptophan appears to be a pathogenic alteration. The
sensitivity of finding MSH2/MLH1 mutations can be further
improved by the detection of large genomic deletions or rear-
rangements. Their contribution may be as high as 36% of all
MSH2 mutations according to Dutch HNPCC mutation
analysis.20 MLH1 mutations are mainly single nucleotide
changes. The only country with a high proportion of MLH1
deletion is Finland, where a founder effect associated with a
3.5 kb deletion encompassing exon 16 has been identified.10
Our studies of RNA transcripts suggest that the frequency of
large intragenic deletions without involvement of the 5′ and 3′
ends of the MSH2 or MLH1 genes is low in the population
studied here. However, more extensive studies are necessary in
order to describe the actual proportion of such changes among
HNPCC families in this population. Loss of exon 16 detected at
the RNA level may suggest the presence of a large genomic
deletion. This is not, however, caused by the 3.5 kb genomic
deletion observed frequently in Finland, since in experiments
using long PCR with primers for exons 15 and 17 we observed
only the product of normal length.18 Two of the most frequent
mutations identified in Poland were also found in Lithuanian
families, suggesting a common history. Poland and the Baltic
States may have more common mutations than reported here
since the number of samples from Estonia, Latvia, and
Lithuania were too small to make the appropriate compari-
sons. In summary, it seems likely that the MSH2 and MLH1
changes described here are representative of the majority of
HNPCC mutations in families from this region. Therefore, we
believe it is justified to develop a DNA testing strategy based
on the preferential analysis of changes identified from this
population.
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E853A MSH2 Yes ? Yes sHNPCC(+) No
I19F MLH1 No Yes - ATPase Yes sHNPCC(+) NE
L292P MLH1 No Yes - ATPase Yes sHNPCC(+) NE
R687W MLH1 Yes Yes - potentialy PMS2 binding Yes sHNPCC(+) Yes
*Alteration not found in any of 100 normal controls.
NE, not examined.
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A Jawień, Z Banaszkiewicz, Department of Surgery, Medical
Academy, Bydgoszcz, Poland
J Kowalczyk, Paediatric Haematology and Oncology Clinics, Medical
Academy, Lublin, Poland
D Czudowska, Oncology Diagnostic Centre, Legnica, Poland
P E Goretzki, G Moeslein, Department of Surgery, University of
Dusseldorf, Germany
Correspondence to: Dr G Kurzawski, Department of Genetics and
Pathology, Pomeranian Academy of Medicine, ul Polabska 4 Szczecin
70-115, Poland; gkurz@sci.pam.szczecin.pl
REFERENCES
1 Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis
colorectal cancer. J Med Genet 1999;36:801-18.
2 Papadopoulos N, Nicolaides NC, Wei YF. Mutation of a mutL homolog
in hereditary colon cancer. Science 1994;263:1625-9.
3 Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R,
Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M. Mutations of a
mutS homolog in hereditary nonpolyposis colorectal cancer. Cell
1993;75:1215-25.
4 Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, Yuasa
Y. Germ-line mutation of the hMSH6/GTBP gene in an atypical
hereditary nonpolyposis colorectal cancer kindred. Cancer Res
1997;57:3920-3.
5 Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM,
Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM. Mutations of two
PMS homologues in hereditary nonpolyposis colon cancer. Nature
1994;371:75-80.
6 Peltomäki P. Genotype and phenotype in hereditary nonpolyposis colon
cancer: a study of families with different vs shared predisposing
mutations. Familial Cancer 2001;1:9-15.
7 Peltomaki P, Vasen HFA, ICG-HNPCC: Bisgaard M, Buerstedde M,
Friedl W, Grandjouan S, Hutter P, Kohonen-Corish M, Kolodner R,
Kurzawski G, Lindblom A, Lynch HT, Piepoli A, Pons de Leon M, Radice
P, Thibodeau S, Weber W, West S, Wijnen J. Mutations predisposing to
hereditary nonpolyposis colorectal cancer: database and results of a
collaborative study. The International Collaborative Group on Hereditary
Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113:1146-58.
8 Froggatt NJ, Green J, Brassett C, Evans G, Bishop DT, Kolodner R,
Maher ER. A common MSH2 mutation in English and North American
HNPCC families: origin, phenotypic expression, and sex specific
differences in colorectal cancer. J Med Genet 1999;36:97-102.
9 Nystrom-Lahti M, Wu Y, Moisio AL, Hofstra RM, Osinga J, Mecklin JP,
Jarvinen HJ, Leisti J, Buys CH, de la Chapelle A, Peltomaki P. DNA
mismatch repair gene mutations in 55 kindreds with verified or putative
hereditary non-polyposis colorectal cancer. Hum Mol Genet
1996;5:763-9.
10 Nystrom-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA,
Moisio AL, Jarvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B, de la
Chapelle A, Peltomaki P. Founding mutations and Alu-mediated
recombination in hereditary colon cancer. Nat Med 1995;1:1203-6.
11 Jager AC, Bisgaard ML, Myrhoj T, Bernstein I, Rehfeld JF, Nielsen FC.
Reduced frequency of extracolonic cancers in hereditary nonpolyposis
colorectal cancer families with monoallelic hMLH1 expression. Am J Hum
Genet. 1997;61:129-38.
12 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for
hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome)
proposed by the International Collaborative group on HNPCC.
Gastroenterology 1999;116:1453-6.
13 Kladny J, Moslein G, Myrhoj T, Kurzawski G, Jakubowska A, Debniak
T, Petriczko W, Kozlowski M, Amawi AL, Flicinski J, Banaszkiewicz A,
Rychter P, Lubinski J. Nuclear pedigree criteria of suspected HNPCC.
Hered Cancer Clin Pract (in press).
14 Lahiri DK, Schnabel B. DNA isolation by rapid methods from human
blood samples: effects of MgCl2, EDTA, storage time, and temperature on
DNA yield and quality. Biochem Genet 1993;31:321-8.
15 Kurzawski G, Safranow K, Suchy J, Chlubek D, Scott RJ, Lubinski J.
Mutation analysis of MLH1 and MSH2 genes performed by denaturing
high-performance liquid chromatography. J Biochem Biophys Methods
2002;51:89-100.
16 Kolodner R, Hall NR, Lipford J, Kane MF, Morrison PT, Finan PJ, Burn J,
Chapman P, Earabino C, Merchant E, Bishop DT. Structure of the human
MLH1 locus and analysis of a large hereditary nonpolyposis colorectal
carcinoma kindred for mlh1 mutations. Cancer Res 1995;55:242-8.
17 Wijnen J, Vasen H, Khan PM, Menko FH, van der Klift H, van Leeuwen
C, van den Broek M, van Leeuwen-Cornelisse I, Nagengast F,
Meijers-Heijboer A, Lindhout D, Griffioen G, Cats A, Kleibeuker J,
Varesco L, Bertario L, Bisgaard ML, Mohr J, Fodde R. Seven new
mutations in hMSH2, an HNPCC gene, identified by denaturing
gradient-gel electrophoresis. Am J Hum Genet 1995;56:1060-6.
18 Jakubowska A, Gorski B, Kurzawski G, Debniak T, Hadaczek P,
Cybulski C, Kladny J, Oszurek O, Scott RJ, Lubinski J. Optimization of
experimental conditions for RNA-based sequencing of MLH1 and MSH2
genes. Hum Mutat 2001;17:52-60.
19 Park JG, Vasen HF, Park KJ, Peltomaki P, Ponz de Leon M,
Rodriguez-Bigas MA, Lubinski J, Beck NE, Bisgaard ML, Miyaki M,
Wijnen JT, Baba S, Lynch HT. Suspected hereditary nonpolyposis
colorectal cancer: International Collaborative Group on Hereditary
Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of
genetic diagnosis. Dis Colon Rectum 1999;42:710-15.
20 Wijnen J, van der Klift H, Vasen H, Khan PM, Menko F, Tops C, Meijers
Heijboer H, Lindhout D, Moller P, Fodde R. MSH2 genomic deletions are
a frequent cause of HNPCC. Nat Genet 1998;20:326-8.
Online mutation report 5 of 5
www.jmedgenet.com
 on O











enet: first published as 10.1136/jm
g.39.10.e65 on 1 O
ctober 2002. D
ow
nloaded from
 
